| __timestamp | Neurocrine Biosciences, Inc. | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 46425000 | 855506000 |
| Thursday, January 1, 2015 | 81491000 | 996170000 |
| Friday, January 1, 2016 | 94291000 | 1047690000 |
| Sunday, January 1, 2017 | 121827000 | 1324625000 |
| Monday, January 1, 2018 | 160524000 | 1416476000 |
| Tuesday, January 1, 2019 | 200000000 | 1754540000 |
| Wednesday, January 1, 2020 | 275000000 | 1829537000 |
| Friday, January 1, 2021 | 328100000 | 3051100000 |
| Saturday, January 1, 2022 | 463800000 | 2540300000 |
| Sunday, January 1, 2023 | 565000000 | 3162900000 |
| Monday, January 1, 2024 | 731100000 | 3630300000 |
Unleashing the power of data
In the competitive world of biotechnology, innovation is the lifeblood of success. Over the past decade, Vertex Pharmaceuticals Incorporated and Neurocrine Biosciences, Inc. have been at the forefront of this race, investing heavily in research and development (R&D) to drive breakthroughs. From 2014 to 2023, Vertex Pharmaceuticals consistently outpaced Neurocrine Biosciences in R&D spending, with Vertex's investment peaking at approximately $3.16 billion in 2023, a staggering 460% increase from 2014. In contrast, Neurocrine Biosciences saw a significant rise in their R&D expenses, growing by over 1,100% to reach $565 million in the same year. This substantial growth reflects the industry's dynamic nature and the relentless pursuit of innovation. As these companies continue to push the boundaries of science, their commitment to R&D underscores the critical role of investment in shaping the future of healthcare.
Bristol-Myers Squibb Company vs Vertex Pharmaceuticals Incorporated: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Vertex Pharmaceuticals Incorporated and Dr. Reddy's Laboratories Limited
Vertex Pharmaceuticals Incorporated vs Jazz Pharmaceuticals plc: Strategic Focus on R&D Spending
R&D Insights: How Vertex Pharmaceuticals Incorporated and Bausch Health Companies Inc. Allocate Funds
Research and Development Investment: Takeda Pharmaceutical Company Limited vs Neurocrine Biosciences, Inc.
Analyzing R&D Budgets: Genmab A/S vs Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. or Blueprint Medicines Corporation: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Lantheus Holdings, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and TG Therapeutics, Inc.
Comparing Innovation Spending: Neurocrine Biosciences, Inc. and Ionis Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. vs Ultragenyx Pharmaceutical Inc.: Strategic Focus on R&D Spending
Research and Development Investment: Neurocrine Biosciences, Inc. vs Protagonist Therapeutics, Inc.